GlassScriptPhysician profile
Andrew Shipe Dothard
NPI 1164809232
$75,211.24
in general payments reported to CMS, 2019-2025
16 companies · $51K in 2025
The $51K reported for 2025 was more than what 95% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $160 · 2021: $99.95 · 2022: $415 · 2023: $274 · 2024: $23K · 2025: $51K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $42K · Consulting Fee: $20K · Travel and Lodging: $9,630 · Food and Beverage: $2,742 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,649.33 |
| Consulting Fee | $20,138.00 |
| Travel and Lodging | $9,629.76 |
| Food and Beverage | $2,742.12 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $51,727.29 | 2024-2025 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $19,887.39 | 2022-2025 | Tagrisso, Enhertu, Imfinzi |
| Daiichi Sankyo INC. | $2,034.17 | 2024-2025 | Enhertu, Datroway |
| Novocure INC. | $432.79 | 2022-2024 | Optune |
| Seagen INC. | $294.98 | 2020-2022 | |
| Incyte Corporation | $198.95 | 2019-2021 | |
| Iovance Biotherapeutics, INC. | $168.54 | 2025 | Amtagvi |
| Takeda Pharmaceuticals U.S.A., INC. | $99.99 | 2019 | |
| Jazz Pharmaceuticals INC. | $90.35 | 2023 | |
| Abbvie INC. | $74.60 | 2019 | |
| Genentech USA, INC. | $64.99 | 2020 | |
| Janssen Biotech, INC. | $59.99 | 2019 | |
| Janssen Scientific Affairs, LLC | $35.29 | 2025 | Rybrevant |
| Ipsen Biopharmaceuticals, INC | $24.25 | 2025 | Onivyde |
| E.R. Squibb & Sons, L.L.C. | $17.67 | 2024 | Opdivo |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Dothard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.